Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
8.44% $1.670
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 59.25 mill |
EPS: | -0.310 |
P/E: | -5.39 |
Earnings Date: | May 03, 2024 |
SharesOutstanding: | 35.48 mill |
Avg Daily Volume: | 0.143 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -5.39 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.92x |
Company: PE -5.39 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.366 (-78.06%) $-1.304 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.505 - 1.835 ( +/- 9.88%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-12 | Taitel Haya | Buy | 9 500 | Ordinary Shares, par value NIS 0.0000769 per share |
2024-01-10 | Taitel Haya | Buy | 7 615 | Ordinary Shares, par value NIS 0.0000769 per share |
2024-01-01 | Taitel Haya | Buy | 108 333 | Stock Option (right to buy) |
2024-01-01 | Garceau Roger | Buy | 108 333 | Stock Option (right to buy) |
2024-01-01 | Malca Yonatan | Buy | 108 333 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 89 transactions |
Buy: 4 333 534 | Sell: 4 161 674 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.670 (8.44% ) |
Volume | 0.124 mill |
Avg. Vol. | 0.143 mill |
% of Avg. Vol | 87.22 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.